News
-
-
PRESS RELEASE
Valneva et Pfizer annoncent de nouvelles données positives de Phase 2 après une vaccination de rappel pour le candidat vaccin contre la maladie de Lyme
Valneva et Pfizer rapportent des données positives de Phase 2 pour le candidat vaccin contre la maladie de Lyme, montrant une forte réponse immunitaire post-vaccination de rappel -
PRESS RELEASE
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Valneva and Pfizer announce positive Phase 2 booster results for Lyme disease vaccine candidate, VLA15-221, showing strong immune response and safety profile, advancing towards Phase 3 trials -
-
-
-
-
-
-
PRESS RELEASE
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE (ISIN: FR0004056851) with a BUY recommendation and EUR 8.60 price target. H1 product sales slightly below consensus but gross margin improving. Valneva maintains full-year guidance